Respiratory News and Research

RSS

Diabetes control in COPD patients could improve outcomes, length of hospital stays and risk of death

A new study in the journal Respirology reveals that patients with diabetes who are hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) experience longer time in the hospital and are also at an increased risk of death, compared to those without diabetes.

22 Jun 2010

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Palatin Technologies, Inc. today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans.

21 Jun 2010

End Duchenne Day to be celebrated on June 26, 2010: PPMD

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy, announced that the Mayor of Denver, Colorado, John W. Hickenlooper, has proclaimed June 26, 2010 "End Duchenne Day" in recognition of PPMD's 16th Annual Connect Conference. Denver is playing host to the country's largest Duchenne-specific, international conference, June 24 – 27, 2010.

19 Jun 2010

Ingen Technologies to exhibit, sponsor at upcoming Medtrade conference

Ingen Technologies, Inc., a medical device manufacturer with an emerging new medical product line for the $8B respiratory market, announced today that the company has officially accepted to be an exhibitor and sponsor at the upcoming Medtrade conference in Atlanta, Georgia from November 15-18, 2010 at the Georgia World Congress Center.

19 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.

19 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Research examines relationship between body-image distortion and weight-loss behaviors

Normal weight and underweight teenage girls who falsely believe they are overweight are at significantly greater risk of succumbing to unnecessary and unsafe weight-loss behaviors than girls who can accurately assess their weight status, according to new research by a University of Illinois expert in eating disorders and body-image perception.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Roche implements risk mitigation plan in taspoglutide Phase III programme

Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

18 Jun 2010

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

18 Jun 2010

Light cigarettes to be phased out as part of Family Smoking Prevention and Tobacco Control Act

Effective June 22, 2010, the most popular selling cigarettes – light cigarettes – will be phased out as part of the Family Smoking Prevention and Tobacco Control Act, which was signed into law on June 22, 2009. This historic day provides an opportunity for the 70 percent of smokers who want to quit to finally end their addiction to these deadly products.

18 Jun 2010

UF administers Lumizyme for late-onset Pompe disease

The first commercially available treatment in the United States for patients with late-onset Pompe disease was administered Wednesday, June 16, at the University of Florida.

18 Jun 2010

Researchers study risks and consequences of cigarette smoking in people living in multiple-unit housing

In an effort to protect children from harmful tobacco smoke exposure, health and medical professionals are pushing for a ban on smoking in public housing in a report appearing in this week's New England Journal of Medicine.

18 Jun 2010

Researchers make significant headway in fight against SMA

Researchers at the University of Utah are making strides in understanding and combating a motor neuron disease known as Spinal Muscular Atrophy. The spinal muscular atrophies are a group of inherited diseases that cause progressive degeneration of motor nerves resulting in muscle weakness. The most common form of the disorder, due to the deletion of a critical gene on chromosome 5, is currently the leading cause of inherited infant and child mortality.

18 Jun 2010

2009 H1N1 pandemic influenza vaccine protects against 1918 influenza virus: Report

Mice injected with a 2009 H1N1 pandemic influenza vaccine and then exposed to high levels of the virus responsible for the 1918 influenza pandemic do not get sick or die, report scientists funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

17 Jun 2010

Daily use of probiotics reduces VAP in critically ill patients: New research

Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.

17 Jun 2010

State round-up: Calif. orders review of insurers' planned rate hikes; S.D. targets young smokers

"California health insurance regulators have ordered independent reviews of rate hikes being sought by four of the state's largest insurers, a move that could lead to smaller increases for consumers. The action comes after an outside analysis found significant errors in a recent rate filing by Anthem Blue Cross, leading it to cancel increases of as much as 39% for hundreds of thousands of policyholders. , to be announced Wednesday by The California Department of Insurance's findings are to be announced Wednesday" (Helfand, 6/16).

17 Jun 2010

UF doctors administer newly available therapy for late-onset Pompe disease

The first commercially available treatment in the United States for patients with late-onset Pompe disease was administered today (Wednesday, June 16) at the University of Florida.

17 Jun 2010

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

Horizon Pharma, Inc., announced today that data from the Phase 3 U.S. registration study of LODOTRA, a circadian cytokine modulator and novel modified-release, low-dose prednisone tablet, showed a statistically significant improvement in American College of Rheumatology response criteria in patients with rheumatoid arthritis.

16 Jun 2010

Respiratory News and Research

Diabetes control in COPD patients could improve outcomes, length of hospital stays and risk of death

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

End Duchenne Day to be celebrated on June 26, 2010: PPMD

Ingen Technologies to exhibit, sponsor at upcoming Medtrade conference

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Research examines relationship between body-image distortion and weight-loss behaviors

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Roche implements risk mitigation plan in taspoglutide Phase III programme

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

Light cigarettes to be phased out as part of Family Smoking Prevention and Tobacco Control Act

UF administers Lumizyme for late-onset Pompe disease

Researchers study risks and consequences of cigarette smoking in people living in multiple-unit housing

Researchers make significant headway in fight against SMA

2009 H1N1 pandemic influenza vaccine protects against 1918 influenza virus: Report

Daily use of probiotics reduces VAP in critically ill patients: New research

State round-up: Calif. orders review of insurers' planned rate hikes; S.D. targets young smokers

UF doctors administer newly available therapy for late-onset Pompe disease

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News